Article

<i>In vivo</i> Auto-tuning of Antibody-Drug Conjugate Delivery for Effective Immunotherapy using High-Avidity, Low-Affinity Antibodies

2024-04-10

Abstract excerpt

Antibody-drug conjugates (ADCs) have experienced a surge in clinical approvals in the past five years. Despite this success, a major limitation to ADC efficacy in solid tumors is poor tumor penetration, which leaves many cancer cells untargeted. Increasing antibody doses or co-administering ADC with an unconjugated antibody can improve tumor penetration and increase efficacy when target receptor expression is high...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 8c760207-cdd1-5f7d-ac6c-98526372a1fe
DOI: 10.1101/2024.04.06.588433

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

<i>In vivo</i> Auto-tuning of Antibody-Drug Conjugate Delivery for Effective Immunotherapy using High-Avidity, Low-Affinity AntibodiesDOI 10.1101/2024.04.06.588433Read

Binding and functional profiling of antibody mutants guides selection of optimal candidates as antibody drug conjugates.Semantic proximity Read

Expanding the repertoire of Antibody Drug Conjugate (ADC) targets with improved tumor selectivity and range of potent payloads through in-silico analysis.Semantic proximity Read

Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistanceSemantic proximity Read

Evaluation of RC48-ADC in combination with PRaG regimen: An open-label, prospective, multicentre study assessing efficacy and safety for advanced refractory HER2-expressing solid tumors (PRaG3.0 Study Protocol)Semantic proximity Read

Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors.Semantic proximity Read

High Affinity Promotes Internalization of Engineered Antibodies Targeting FGFR1Semantic proximity Read

Structure-guided computational design and mechanistic understanding of the p95HER2-targeting NAZ-mAb antibody and its variantsSemantic proximity Read

Linker Design in Antibody-Drug Conjugates: Balancing Stability, Release and ResistanceSemantic proximity Read

Precision Immunotherapy: Revolutionizing Cancer Treatment With Targeted Innovations.Semantic proximity Read

Clinical Potential of Antibody–Drug Conjugates in Early-Phase Clinical Trials for Late-Line Treatment of Advanced Solid TumorsSemantic proximity Read

Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumorsSemantic proximity Read

The Target Atlas for Antibody-Drug Conjugates across Solid CancersSemantic proximity Read